Synokem Pharma Gets CDSCO Panel Nod To Manufacture, Market Antidiabetic FDC

Teneligliptin is a dipeptidyl peptidase 4 (DPP-4) inhibitor. Teneligliptin inhibits the action of DPP-4 enzymes and slows down the rapid degradation of incretins. It also increases insulin synthesis by the pancreas and decreases glucagon levels which are a counter-hormone of insulin, thereby further decreasing blood sugar levels.

Metformin is a biguanide antihyperglycemic used in conjunction with diet and exercise for glycemic control in type 2 diabetes mellitus. It is also used off-label for insulin resistance in polycystic ovary syndrome (PCOS). Metformin is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients ≥10 years old with type 2 diabetes mellitus.

Dapagliflozin is in a class of medications called sodium-glucose co-transporter 2 (SGLT2) inhibitors. It lowers blood sugar by causing the kidneys to get rid of more glucose in the urine. By inhibiting SGLT2, dapagliflozin blocks the reabsorption of filtered glucose in the kidney, increasing urinary glucose excretion and reducing blood glucose levels. Its mechanism of action is independent of pancreatic β cell function and modulation of insulin sensitivity.

At the recent SEC meeting for Endocrinology and Metabolism held on the 20th and 21st of April 2023, the expert panel reviewed the justification for Phase III CT study waiver for the proposed FDC based on Phase III clinical trial study conducted on FDC of Dapagliflozin plus Teneligliptin (5mg+20mg & 10mg+20mg) tablets.